on July 29, 2002
Published online before print July 29, 2002, doi: 10.1161/01.HYP.0000028001.65341.AA
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 21, 2002
From the Institute of Experimental and Clinical Pharmacology and Toxicology, Medical University of Luebeck, Luebeck, Germany. * To whom correspondence should be addressed. E-mail: dendorfe{at}medinf.mu-luebeck.de.
Abstract—Angiotensin II (ANG) is known to facilitate catecholamine release from peripheral sympathetic neurons by enhancing depolarization-dependent exocytosis. In addition, a direct excitation by ANG of peripheral sympathetic nerve activity has recently been described. This study determined the significance of the latter mechanism for angiotensin-induced catecholamine release in the pithed rat. Rats were anesthetized and instrumented for measuring either hemodynamics and renal sympathetic nerve activity or plasma catecholamine concentrations in response to successively increasing doses of angiotensin infusions. Even during ganglionic blockade by hexamethonium (20 mg/kg), angiotensin dose-dependently elevated sympathetic nerve activity, whereas blood pressure--equivalent doses of phenylephrine were ineffective. Independently of central nervous sympathetic activity and ganglionic transmission, angiotensin (0.1 to 1 µg/kg) also induced an up-to 27-fold increase in plasma norepinephrine levels, reaching 2.65 ng/mL. Preganglionic electrical stimulation (0.5 Hz) raised basal norepinephrine levels 11-fold and further enhanced the angiotensin-induced increase in norepinephrine (4.04 ng/mL at 1 µg/kg ANG). Stimulation of sympathetic nerve activity and norepinephrine release were suppressed by candesartan (1 mg/kg) or tetrodotoxin (100 µg/kg), respectively. Angiotensin enhanced plasma norepinephrine, heart rate, and sympathetic nerve activity at similar threshold doses (0.3 to 1 µg/kg), but raised blood pressure at a significantly lower dose (0.01 µg/kg). It is concluded that direct stimulation of ganglionic angiotensin type 1 (AT1) receptors arouses electrical activity in sympathetic neurons, leading to exocytotic junctional catecholamine release. In both the absence and presence of preganglionic sympathetic activity, this mechanism contributes significantly to ANG-induced enhancement of catecholamine release.
Revised on April 15, 2002
Angiotensin II Induces Catecholamine Release by Direct Ganglionic Excitation
Andreas Dendorfer*;
Key words: angiotensin II • angiotensin antagonist • catecholamines • sympathetic nervous system • electric stimulation • rats
This article has been cited by other articles:
 |
|
 |
|
  T. Kawada, M. Mizuno, S. Shimizu, K. Uemura, A. Kamiya, and M. Sugimachi Angiotensin II disproportionally attenuates dynamic vagal and sympathetic heart rate controls Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1666 - H1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Burg, B. Graeber, A. Vashist, D. Collins, C. Earley, J. Liu, R. Lampert, and R. Soufer Noninvasive Detection of Risk for Emotion Provoked Myocardial Ischemia Psychosom Med, January 1, 2009; 71(1): 14 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurihara, Y. Ozawa, N. Nagai, K. Shinoda, K. Noda, Y. Imamura, K. Tsubota, H. Okano, Y. Oike, and S. Ishida Angiotensin II Type 1 Receptor Signaling Contributes to Synaptophysin Degradation and Neuronal Dysfunction in the Diabetic Retina Diabetes, August 1, 2008; 57(8): 2191 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsukawa and T. Miyamoto Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism? Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1873 - R1879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Acosta, V. Mendoza, E. Castro, and H. Cruzblanca Modulation of a Delayed-Rectifier K+ Current by Angiotensin II in Rat Sympathetic Neurons J Neurophysiol, July 1, 2007; 98(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurihara, Y. Ozawa, K. Shinoda, N. Nagai, M. Inoue, Y. Oike, K. Tsubota, S. Ishida, and H. Okano Neuroprotective Effects of Angiotensin II Type 1 Receptor (AT1R) Blocker, Telmisartan, via Modulating AT1R and AT2R Signaling in Retinal Inflammation Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5545 - 5552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Campos, R. Iliescu, M. A. P. Fontes, W.-P. Schlegel, M. Bader, and O. C. Baltatu Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2371 - H2376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Ma, K. Bielefeldt, Z. Y. Tan, C. A. Whiteis, V. Snitsarev, F. M. Abboud, and M. W. Chapleau Dual mechanisms of angiotensin-induced activation of mouse sympathetic neurones J. Physiol., May 15, 2006; 573(1): 45 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Ganta, N. Lu, B. G. Helwig, F. Blecha, R. R. Ganta, L. Zheng, C. R. Ross, T. I. Musch, R. J. Fels, and M. J. Kenney Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1683 - H1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kouyama, T. Suganami, J. Nishida, M. Tanaka, T. Toyoda, M. Kiso, T. Chiwata, Y. Miyamoto, Y. Yoshimasa, A. Fukamizu, et al. Attenuation of Diet-Induced Weight Gain and Adiposity through Increased Energy Expenditure in Mice Lacking Angiotensin II Type 1a Receptor Endocrinology, August 1, 2005; 146(8): 3481 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. El Muayed Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: A possible contributing mechanism J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1144 - 1144. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Raasch, P. Dominiak, A. Ziegler, and A. Dendorfer Reduction of Vascular Noradrenaline Sensitivity by AT1 Antagonists Depends on Functional Sympathetic Innervation Hypertension, September 1, 2004; 44(3): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin and R. M. Touyz From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446. [Full Text] [PDF]
|
|
|
|
|
|
D. F. McKeogh, T. L. O'Donaughy, and V. L. Brooks NO and endogenous angiotensin II interact in the generation of renal sympathetic nerve activity in conscious rats Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1258 - H1265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Grisk and R. Rettig Interactions between the sympathetic nervous system and the kidneys in arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 238 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ma, C. D. Sigmund, S. D. Hingtgen, X. Tian, R. L. Davisson, F. M. Abboud, and M. W. Chapleau Ganglionic Action of Angiotensin Contributes to Sympathetic Activity in Renin-Angiotensinogen Transgenic Mice Hypertension, February 1, 2004; 43(2): 312 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. LaGrange, G. M. Toney, and V. S. Bishop Effect of Intravenous Angiotensin II Infusion on Responses to Hypothalamic PVN Injection of Bicuculline Hypertension, December 1, 2003; 42(6): 1124 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Raasch, B. Jungbluth, U. Schafer, W. Hauser, and P. Dominiak Modification of Noradrenaline Release in Pithed Spontaneously Hypertensive Rats by I1-Binding Sites in Addition to alpha 2-Adrenoceptors J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1063 - 1071. [Abstract] [Full Text] [PDF]
|
|